Merck KGaA drug Pimjetmi is now FDA approved for treating tenosynovial giant cell tumor. This drug complements other rare tumor assets the Germany-based drugmaker has acquired in a series of business deals.
The post Drug Approval Marks Another Win for Merck KGaA’s Rare Tumor Strategy appeared first on MedCity News.
